Records ?

Pediatric Kidney Transplant Recipient Follow-Up Worksheet

The revised worksheet sample is for reference purposes only and is pending OMB approval.

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI^{B.} application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI^{B.} application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
	DOB:
Name: SSN:	
HIC:	Gender:
	Tx Date:
Previous Follow-Up:	Previous Px Stat Date:
T 1 (B) 1 B (
Transplant Discharge Date:	
State of Permanent Residence: ★	
Zip Code: ★	
Provider Information	
Recipient Center:	
Followup Center:	
Followup Center:	
Physician Name: *	
NPI: *	
	C. Transplant Contra
	Transplant Center
5 II	Non Transplant Center Specialty Physician
Follow-up Care Provided By: *	Primary Care Physician
	Other Specify
Charifu	
Specify:	
Donor Information	
UNOS Donor ID #:	
Donor Type:	
Patient Status	
Date: Last Seen, Retransplanted or Death★	
	C LIVING
Patient Status: *	O DEAD
	© RETRANSPLANTED
	RETRANSPLANTED
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
Hospitalizations:	
Has the patient been hospitalized since the last patient status date:★	C YES NO UNK
rias the patient been hospitalized since the last patient status date.	YES NO VONK
Number of Hospitalizations:	St=
	Disease Recurrence:
	○ No recurrence
TRR Diagnosis:	Suspected recurrence (not confirmed or unknown is confirmed by biopsy)
	Biopsy confirmed recurrence
	C Unknown
Noncompliance:	
Was there evidence of noncompliance with immunosuppression	
medication during this follow-up period that compromised the patient's recovery:	C YES C NO C UNK

Functional Status: *				
Cognitive Development: ★	 Definite Cognitive delay/impairment (verified by IQ score <70 or unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties) No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment) Not Assessed 			
Motor Development: ★	 Definite Motor delay/impairment (verified by physical exam or unambiguous behavioral observation) Probable Motor delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Motor delay/impairment (not judged to be more likely than not, but with some indications of motor delay/impairment) No Motor delay/impairment (no obvious indicators of motor delay/impairment) Not Assessed 			
Academic Progress: [*] ⊀	 Within One Grade Level of Peers Delayed Grade Level Special Education Not Applicable < 5 years old Status Unknown 			
Academic Activity Level:*	 Full academic load Reduced academic load Unable to participate in academics due to disease or condition Not Applicable < 5 years old/ High School graduate Status Unknown 			
Primary Insurance at Follow-up: * Specify:				
Clinical Information				
Date of Measurement: *				
Height: [★]	ft. in. cm %ile ST=			
Weight: *	lbs. kg %ile ST=			
BMI:	kg/m ² %ile			
Is growth hormone therapy used during this follow-up period: *	O YES O NO O UNK			
Urine Protein Found By Any Method:	O YES O NO O UNK			
Diabetes onset during the follow-up period:★	C YES O NO C UNK			
If yes, insulin dependent:	C YES O NO C UNK			
Bone Disease: *				
Fracture in the past year (or since last follow-up):	C YES C NO C UNK			
(2. 2. 2. 3. 4. 2. 2. 2. 2. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.				
	Spine-compression fracture # of fractures:			
Specify Location and number of fractures:	Extremity # of fractures:			
	Other # of fractures:			
AVN (avascular necrosis):	C YES O NO C UNK			
Graft Status: ★	Functioning Failed			
If death is indicated for the recipient, and the death was a result of some other	er factor unrelated to graft failure, select Functioning.			

If Functioning, Most Recent Serum Creatinine:	mg/dl
Date of Failure:	
Primary Cause of Graft Failure:	
Other, Specify:	
Contributory causes of graft failure:	
Acute Rejection	O YES O NO O UNK
Chronic Rejection	C YES O NO UNK
Graft Thrombosis	C YES O NO UNK
Infection	C YES O NO O UNK
Urological Complications	C YES O NO O UNK
Patient Noncompliance	C YES O NO C UNK
Recurrent Disease	O YES O NO O UNK
BK (Polyoma) Virus	C YES C NO C UNK
Other, Specify:	
	© NO
	YES, RESUMED MAINTENANCE DIALYSIS
Dialysis Since Last Follow-Up: ★	YES, NO MAINTENANCE RESUMPTION
	YES, MAINTENANCE RESUMPTION UNKNOWN
	UNKNOWN
Date Maintenance Dialysis Resumed:	
Select a Dialysis Provider:	
Provider #:	
Provider #: Provider Name:	
	Yes, at least one episode treated with anti-rejection agent Yes, none treated with additional anti-rejection agent No Unknown
Provider Name: Did patient have any acute rejection episodes during the follow-up	Yes, none treated with additional anti-rejection agentNo
Provider Name: Did patient have any acute rejection episodes during the follow-up period: *	Yes, none treated with additional anti-rejection agent No Unknown Biopsy not done Yes, rejection confirmed Yes, rejection not confirmed
Did patient have any acute rejection episodes during the follow-up period: * Was biopsy done to confirm acute rejection:	 Yes, none treated with additional anti-rejection agent No Unknown Biopsy not done Yes, rejection confirmed Yes, rejection not confirmed Unknown Positive Negative Not Done
Did patient have any acute rejection episodes during the follow-up period: * Was biopsy done to confirm acute rejection: CMV IgG: **	Yes, none treated with additional anti-rejection agent No Unknown Biopsy not done Yes, rejection confirmed Yes, rejection not confirmed Unknown Positive Negative Not Done UNK/Cannot Disclose Positive Negative Negative Not Done
Did patient have any acute rejection episodes during the follow-up period: * Was biopsy done to confirm acute rejection: CMV IgG: * CMV IgM: *	Yes, none treated with additional anti-rejection agent No Unknown Biopsy not done Yes, rejection confirmed Yes, rejection not confirmed Unknown Positive Negative Not Done UNK/Cannot Disclose Negative Not Done UNK/Cannot Disclose

Post Tx De Novo Solid Tumor:	G YES G NO G UNK
De Novo Lymphoproliferative disease and Lymphoma:	G YES G NO G UNK
Tractment	
Treatment	
Biological or Anti-viral therapy:	YES NO Unknown/Cannot disclose
	Acyclovir (Zovirax)
	Cytogam (CMV)
	Gamimune
	Gammagard
	Ganciclovir (Cytovene)
If Yes, check all that apply:	Valgancyclovir (Valcyte)
	HBIG (Hepatitis B Immune Globulin)
	☐ Flu Vaccine (Influenza Virus)
	Lamivudine (Epivir) (for treatment of Hepatitis B)
	Valacyclovir (Valtrex)
	Other, Specify
	- Chief, Optiony
Specify:	
Specify:	
Treatment for BK (polyoma) virus:	C YES NO
	Yes, Immunosuppression reduction
	Yes, Cidofovir
If Yes, check all that apply:	☐ Yes, IVIG
	Yes, Type Unknown
	Yes, Other, Specify
Specify:	
Other therapies:	C YES C NO
Other therapies.	TES NO
	Photopheresis
If Yes, check all that apply:	Plasmapheresis
	Total Lymphoid Irradiation (TLI)
Immunosuppressive Information Previous Validated Maintenance Follow-Up Medications:	
Trevious validated maintenance rollow op medications.	
	Yes, same as previous validated report
Were any medications given during the follow-up period for maintenance: ★	Yes, but different than previous validated report
	C None given
Did the physician discontinue all maintenance immunosuppressive medications:	C YES C NO
Did the patient participate in any clinical research protocol for immunosuppressive medications:	C YES C NO
Specify:	
Immunosuppressive Medications	
View Immunosuppressive Medications	
Definitions Of Immunosuppressive Follow-Up Medications	
For each of the immunosuppressant medications listed, check Previous Maintena	nce (Prev Maint), Current Maintenance (Curr Maint) or Anti-rejection (AR) to indicate all medications that were
prescribed for the recipient during this follow-up period, and for what reason. If a m Previous Maintenance (Prev Maint) includes all immunosuppressive medications	edication was not given, leave the associated box(es) blank. given during the report period, which covers the period from the last clinic visit to the current clinic visit, for varying
periods of time which may be either long-term or intermediate term with a tapering	of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: pamycin). This does not include any immunosuppressive medications given to treat rejection episodes.

Current Maintenance (Curr Maint) includes all immunosuppressive medications given at the current clinic visit to begin in the next report *for varying periods of time which may be either long-term or intermediate term with a tapering of the dosage until the drug is either eliminated or replaced by another long-term maintenance drug (example: Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppressive medications given to treat rejection episodes.*

Anti-rejection (AR) immunosuppression includes all immunosuppressive medications given for the purpose of treating an acute rejection episode since the last clinic visit (example: Methylprednisolone, Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: from Tacrolimus to Cyclosporine; or from Mycophenolate Mofetil to Azathioprine) because of rejection, the drugs should not be listed under AR immunosuppression, but should be listed under maintenance immunosuppression.

Note: The Anti-rejection field refers to any anti-rejection medications since the last clinic visit, not just at the time of the current clinic visit.

If an immunosuppressive medication other than those listed is being administered (e.g., new monoclonal antibodies), select Previous Maint, or Current Maint, or AR next to Other Immunosuppressive Medication field, and enter the full name of the medication in the space provided. **Do not list non-immunosuppressive medications.**

	Prev Maint	Curr Maint	AR	
Steroids (Prednisone, Methylprednisolone, Solumedrol, Medrol, Decadron)				
Atgam (ATG)				
OKT3 (Orthoclone, Muromonab)				
Thymoglobulin				
Simulect - Basiliximab				
Zenapax - Daclizumab				
Azathioprine (AZA, Imuran)				
EON (Generic Cyclosporine)				
Gengraf (Abbott Cyclosporine)				
Other generic Cyclosporine, specify brand:				
Neoral (CyA-NOF)				
Sandimmune (Cyclosporine A)				
Mycophenolate Mofetil (MMF, Cellcept, RS61443)				
Tacrolimus (Prograf, FK506)				
Modified Release Tacrolimus FK506E (MR4)				
Sirolimus (RAPA, Rapamycin, Rapamune)				
Myfortic (Mycophenolate Sodium)				
Other Immunosuppressive Medications				
Other Illillianosuppressive Medications	Prev Maint	Curr Maint	AR	
Campath - Alemtuzumab (anti-CD52)				
Cyclophosphamide (Cytoxan)				
Leflunomide (LFL, Arava)				
Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)				
Other Immunosuppressive Medication, Specify				
Other Immunosuppressive Medication, Specify				
Rituximab				
Investigational Immunosuppressive Medications				
	Prev Maint	Curr Maint	AR	
Everolimus (RAD, Certican)				
FTY 720				